A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...